CN102369016A - 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用 - Google Patents

用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用 Download PDF

Info

Publication number
CN102369016A
CN102369016A CN2010800147650A CN201080014765A CN102369016A CN 102369016 A CN102369016 A CN 102369016A CN 2010800147650 A CN2010800147650 A CN 2010800147650A CN 201080014765 A CN201080014765 A CN 201080014765A CN 102369016 A CN102369016 A CN 102369016A
Authority
CN
China
Prior art keywords
site
bmp
administration
biological agent
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800147650A
Other languages
English (en)
Chinese (zh)
Inventor
M·E·P·勾德
M·M·哈斯凯尔
D·施瑞尔
S·A·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of CN102369016A publication Critical patent/CN102369016A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
CN2010800147650A 2009-02-12 2010-02-12 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用 Pending CN102369016A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15190909P 2009-02-12 2009-02-12
US61/151,909 2009-02-12
PCT/US2010/024106 WO2010093925A2 (en) 2009-02-12 2010-02-12 PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE

Publications (1)

Publication Number Publication Date
CN102369016A true CN102369016A (zh) 2012-03-07

Family

ID=42105903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800147650A Pending CN102369016A (zh) 2009-02-12 2010-02-12 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用

Country Status (8)

Country Link
US (5) US20100204123A1 (enExample)
EP (1) EP2396025A2 (enExample)
JP (2) JP5819733B2 (enExample)
CN (1) CN102369016A (enExample)
AU (1) AU2010213575B2 (enExample)
CA (1) CA2752157A1 (enExample)
SG (2) SG2014010680A (enExample)
WO (1) WO2010093925A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
WO2009137613A2 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
BR112021002703A2 (pt) 2018-08-31 2021-05-11 Timothy A. Bertram composições compreendendo vesículas derivadas de células e usos das mesmas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022830A1 (en) * 1996-03-22 2003-01-30 Charette Marc F. Methods for enhancing functional recovery following central nervous system ischemia or trauma

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
AU666291B2 (en) 1990-06-15 1996-02-08 Carnegie Institution Of Washington Gdf-1
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
CZ282231B6 (cs) * 1991-06-05 1997-06-11 The Procter And Gamble Company Prostředek na generování nového růstu kosti v savci
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
CA2129820C (en) 1992-02-12 2003-06-17 Helge Neidhardt Dna sequences encoding novel growth/differentiation factors
WO1994010203A2 (en) 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Op-3-induced morphogenesis
WO1994015966A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-9
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
US5447725A (en) 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
JPH09503903A (ja) 1993-07-09 1997-04-22 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−６
EP0725796A4 (en) 1993-10-08 1999-12-01 Univ Johns Hopkins Growth differentiation factor-10
JP3300500B2 (ja) 1993-10-12 2002-07-08 新日本製鐵株式会社 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1999015191A2 (en) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines having neurotrophic activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
BR0209198A (pt) * 2001-04-26 2004-06-08 Control Delivery Sys Inc Métodos de sìntese de compostos contendo fenol
US8154581B2 (en) 2002-10-15 2012-04-10 Revolutionary Concepts, Inc. Audio-video communication system for receiving person at entrance
DK1677735T3 (da) * 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
EP1750743A4 (en) * 2004-04-29 2009-07-08 Glaxosmithkline Zagreb ORAL PREPARATIONS CONTAINING BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF METABOLIC BONE DISEASES
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
AU2005251741B2 (en) * 2004-06-03 2009-09-24 Genera Istrazivanja D.O.O. Insulin-independent, bone morphogenetic protein (BMP)-mediated uptake of blood glucose by peripheral cells and tissues
US7901395B2 (en) * 2005-08-16 2011-03-08 Borden Jonathan R Catheter having staggered lumens and method
ATE543833T1 (de) 2005-12-22 2012-02-15 Janssen Biotech Inc Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
EP2144624A1 (en) * 2007-05-15 2010-01-20 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
WO2010117047A1 (ja) 2009-04-10 2010-10-14 株式会社ニコン 光学材料、光学素子、及びその製造方法
JP2011211450A (ja) 2010-03-30 2011-10-20 Victor Co Of Japan Ltd 立体映像表示装置、立体映像撮像装置および立体映像表示方法
US9507084B2 (en) 2010-12-03 2016-11-29 Ofs Fitel, Llc Single-mode, bend-compensated, large-mode-area optical fibers designed to accomodate simplified fabrication and tighter bends
US8886307B2 (en) 2012-01-30 2014-11-11 Medtronic, Inc. Adaptive cardiac resynchronization therapy
KR101851912B1 (ko) 2012-06-07 2018-04-24 아사히 가세이 일렉트로닉스 가부시끼가이샤 위치 검출 장치
US9298469B2 (en) 2012-06-15 2016-03-29 International Business Machines Corporation Management of multiple nested transactions
US9405290B1 (en) 2013-01-17 2016-08-02 Kla-Tencor Corporation Model for optical dispersion of high-K dielectrics including defects
JP6154215B2 (ja) 2013-06-28 2017-06-28 株式会社日立国際電気 半導体装置の製造方法、基板処理装置およびプログラム
US9170581B2 (en) 2013-09-30 2015-10-27 Crown Equipment Limited Industrial vehicles with overhead light based localization
JP6541301B2 (ja) 2014-03-28 2019-07-10 キヤノン株式会社 ロボット装置、ロボット装置の制御方法、ロボット制御プログラム、及び記録媒体
US9411440B2 (en) 2014-08-22 2016-08-09 Qualcomm Incorporated Digital ultrasonic emitting base station
US9407762B2 (en) 2014-10-10 2016-08-02 Bank Of America Corporation Providing enhanced user authentication functionalities
US9412814B2 (en) 2014-12-24 2016-08-09 Taiwan Semiconductor Manufacturing Co., Ltd. Structure and formation method of FinFET device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022830A1 (en) * 1996-03-22 2003-01-30 Charette Marc F. Methods for enhancing functional recovery following central nervous system ischemia or trauma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
温纪林 等: "骨形态发生蛋白治疗骨缺损研究进展", 《中华创伤骨科杂志》, vol. 6, no. 3, 31 March 2004 (2004-03-31), pages 333 - 336 *
王敏 等: "骨形态发生蛋白与骨肿瘤", 《肿瘤防治杂志》, vol. 10, no. 5, 31 May 2003 (2003-05-31), pages 545 - 548 *

Also Published As

Publication number Publication date
SG2014010680A (en) 2014-04-28
US20120258917A1 (en) 2012-10-11
US20100204123A1 (en) 2010-08-12
JP2012517482A (ja) 2012-08-02
US20140187486A1 (en) 2014-07-03
WO2010093925A3 (en) 2010-10-28
US20130288966A1 (en) 2013-10-31
EP2396025A2 (en) 2011-12-21
SG173632A1 (en) 2011-09-29
JP5819733B2 (ja) 2015-11-24
WO2010093925A2 (en) 2010-08-19
AU2010213575A1 (en) 2011-08-18
JP2014169336A (ja) 2014-09-18
AU2010213575B2 (en) 2013-11-14
US20140336595A1 (en) 2014-11-13
CA2752157A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
JP5819733B2 (ja) 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与
ES2447516T3 (es) Formulaciones de liberación sostenida que comprenden cristales BMP-7
US8946151B2 (en) Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
JP2009292820A (ja) インスリン治療のための薬学的組成物及びその供給装置
US20020086816A1 (en) Protection and enhancement of erythropoietin-responsive cells, tissues and organs
MX2008015639A (es) Composicion de insulina.
JP5819734B2 (ja) ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
WO2016102463A1 (en) Combination of remifentanil and propofol
AU2013206499A1 (en) Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
AU2013206500A1 (en) Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
Eltrafi Role of Opioid Peptides in the Changes in Blood Pressure and the Baroreflex After Injury in the Rat

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120307